The House and Senate appear to be spinning their wheels when it comes to ending a partial government shutdown that’s headed into its second week due to Congress’ inability to agree on fiscal 2014 funding measures. Although the House has yet to get traction on its efforts to fund specific parts of the federal government through a series of mini-continuing resolutions, it planned to advance yet another one to fully fund the FDA at fiscal 2013 levels through Dec. 15.

The FDA clarified what drug review activities would be affected by the lapse in appropriations. The agency said it will continue reviewing new prescription drug, biologic and generic applications so long as the user fees were paid by Sept. 30. But it is stopping practically all activity involving biosimilars.